The US IPO calendar is the running list of companies that have just sold shares to the public and the ones lined up to do so next. This page tracks recent US listings and the deals still on the runway, with every offer price, debut move and total sourced to a filing, the exchange data or a market tally, and dated to the day we checked it. As of November 9, 2026, the market is quiet by historical standards, and biotech is doing most of the work.

A slow October, and the numbers behind it

Eight IPOs raised a combined $1.2 billion in October 2026, joined by one direct listing, according to Renaissance Capital's October market update published November 2, 2026. That was well below the month's ten-year average of 22 IPOs and $5.1 billion. Six deals raised $100 million or more, and biotechs accounted for seven of the month's nine traditional listings. The Renaissance IPO Index, which tracks newly public US companies, fell 10 percent in October, against a 1 percent loss for the S&P 500. Nineteen companies filed their initial paperwork during the month, so the pipeline is building even as pricings stay thin.

The gap between the $1.2 billion raised and the $5.1 billion ten-year average is the headline for the month. It reflects a market where buyers have been cautious about new, unproven companies while established stocks trade near record highs.

Recent US IPOs, and how they have traded

The clearest read on sentiment is what new stocks do after they price. Here are the operating-company IPOs from the last few weeks, with the offer price from the prospectus and the most recent price from stockanalysis.com as of the November 9, 2026 snapshot. Prices and returns change every session, so treat the recent figures as a reading, not a fixed number.

• Lycia Therapeutics (LYCA) priced at $18.00 on October 23, 2026 and raised about $318 million, the month's largest deal. It climbed 67 percent on its first day, per Renaissance, and recently traded near $30.50.
• Aspen Neuroscience (ASPE) priced at $15.00 on October 30 and recently traded near $12.44, about 17 percent below the offer.
• Bambusa Therapeutics (BBTX) priced at $16.00 on October 30 and recently sat near $15.73.
• City Therapeutics (CTY) priced at $18.00 on October 16 and recently traded near $18.25.
• Amaero (AMRO) priced at $4.25 on October 15 and recently traded near $5.45, up about 28 percent.
• Iambic Therapeutics (IAM) priced at $16.00 on October 15 and recently traded near $10.17, down about 36 percent.
• Retension Pharmaceuticals (RTSN) priced at $12.00 on October 9 and recently traded near $11.04.
• TRex Bio (TRXB) priced at $14.00 on October 9 and recently traded near $13.26.

The spread tells the story. The month's traditional IPOs averaged an 8 percent return from their offer price, Renaissance reported, yet nearly two-thirds finished below where they started. A strong headline debut and a stock that keeps its gains are not the same thing.

The deal that did not happen

Not every filing becomes a listing. OPay, a payments company, did not complete its roughly $304 million US IPO and never commenced trading, according to Renaissance. A pulled deal is a normal part of the calendar: issuers and their banks can stand down when the order book or the price is not there, and that is worth remembering when a name sits on the upcoming list. For how the process runs from filing to first trade, see how an IPO works.

Why biotech is carrying the calendar

Seven of October's nine traditional listings were biotechs, and the pattern has held into November. Small drug developers often go public to fund specific clinical trials, so they come to market in steadier numbers than consumer or technology names, which tend to wait for a friendlier window. That is why a quiet overall calendar can still look busy with biotech tickers, and why a single large non-biotech deal stands out so sharply against the backdrop.

What is next on the calendar

The near-term slate is light. Rezera (RZRA), a Boston biotech, is scheduled to list on the Nasdaq on November 12, 2026, offering about 16.7 million shares at a range of $11 to $13, a deal of roughly $200 million that would value the company near $249 million, per stockanalysis.com. IPO dates are estimates and can move. As of the November 9 snapshot, no other US IPOs were scheduled for the following week.

The one to watch: Anthropic

The quarter's marquee name is Anthropic, the AI company behind the Claude models. Anthropic, PBC filed a Form S-1 with the SEC on October 26, 2026 and amended it on November 2, under file number 333-299633, registering to list on the Nasdaq under the ticker ANT. Renaissance describes an expected mid-November listing as the main event of the fourth quarter and estimates the deal could raise up to $75 billion, which would rank it among the largest US IPOs on record. Those figures come from Renaissance's estimate and the company's filing, not from a completed sale: an S-1 is a registration statement, not a priced deal, and nothing is settled until shares trade. We cover the confirmed details in what is confirmed about the Anthropic IPO, and the related delay at its rival in the OpenAI IPO pushed to 2027.

How to read this page

Every figure here is sourced to a prospectus, the exchange data or Renaissance's market tally, and dated to the day we checked it. Offer prices are fixed once a deal prices; recent prices and returns change every session, so we refresh them when they move materially. This is a record of what has happened and what is scheduled, not a view on any of these stocks. Finance Trend Wire does not make price forecasts or buy, sell or hold calls.